| Identification | Back Directory | [Name]
MP07-66 | [CAS]
1938056-90-6 | [Synonyms]
MP07-66
MP07-66, 10 mM in DMSO
2,2-Diethoxy-N-(4-(hexyloxy)benzyl)ethanamine
Benzenemethanamine, N-(2,2-diethoxyethyl)-4-(hexyloxy)-
MP07-66,MP0766,chronic lymphocytic leukemia,FTY720 analogue,Inhibitor,SET-PP2A complex,inhibit,immunosuppressive effects,MP-07-66,Phosphatase,MP07 66,antitumor effects | [Molecular Formula]
C19H33NO3 | [MOL File]
1938056-90-6.mol | [Molecular Weight]
323.47 |
| Chemical Properties | Back Directory | [Boiling point ]
408.8±35.0 °C(Predicted) | [density ]
0.970±0.06 g/cm3(Predicted) | [form ]
Oil | [pka]
7.67±0.30(Predicted) | [color ]
Colorless to light yellow |
| Hazard Information | Back Directory | [Uses]
MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation[1]. | [References]
[1] Zonta F, et al. Lyn sustains oncogenic signaling in chronic lymphocytic leukemia by strengthening SET-mediated inhibition of PP2A. Blood. 2015;125(24):3747-3755. DOI:10.1182/blood-2014-12-619155 |
|
|